$TPST

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers

Tempest Therapeutics (NASDAQ: TPST) has registered 8,268,495 shares of common stock for resale by existing selling stockholders. These shares were issued as consideration in an Asset Purchase Agreement dated November 19, 2025, for the acquisition of CAR-T and related assets. The company will not receive any proceeds from these resales, which will be conducted by the named selling stockholders, including Matthew Angel and Lotus Capital (BVI) Limited.

Original reporting
Published Mar 31, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers — source image
Decision brief

The 30-second read

$TPSTNeutralMed
01

Why it matters

This event is primarily a liquidity and share supply adjustment, with limited immediate impact on company fundamentals.

02

Market read

While relevant to current shareholders and traders, the event has limited broader market impact.

03

What to watch

Market reaction may be muted if the resale is well-absorbed by existing shareholders; also, the absence of proceeds to the company limits fundamental concerns.

Timing: Immediate, as the registration is recent and resale could occur within weeks.

Background

Tempest Therapeutics registered over 8 million shares for resale by existing shareholders, related to an asset acquisition completed in late 2025.

Company-level read

Ticker impact

$TPSTNeutralMedium confidence
Context

High relevance due to recent share registration and acquisition activity.

Expected impact

Potential short-term downward pressure due to increased share availability; long-term impact depends on subsequent use of proceeds and company performance.

Evidence & confidence

The event is factual and indicates no direct capital influx to the company, but the increased supply could influence stock price dynamics in the near term.

Market effects

Limited sector impact; biotech/pharma sectors may experience minor volatility due to share dilution concerns.

Minimal regional impact; event is company-specific.

Negligible global relevance.

Counterpoint

The share registration could be viewed positively if it signals upcoming strategic initiatives or partnerships, leading to potential stock appreciation in the longer term.

Key entities

  • Tempest Therapeutics

    A biotech company focused on developing novel cancer therapies.

  • Matthew Angel

    A significant shareholder involved in the resale.

  • Lotus Capital (BVI) Limited

    A major shareholder involved in the resale.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.